Drugs known as GLP-1 receptor agonists were initially developed to treat Type 2 diabetes but have become a cultural phenomenon.

The federal government is expected to start a 5-year-long experiment that will provide some limited coverage of obesity medications.

A move to cover expensive weight-loss drugs for Americans on Medicare and Medicaid may be in the works, but any such program could run into problems with voluntary participation and concerns about expense.